Page last updated: 2024-11-13
ati 5923
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Description
tecarfarin: a vitamin K epoxide reductase inhibitor; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
| ID Source | ID |
|---|---|
| PubMed CID | 54718618 |
| CHEMBL ID | 2105664 |
| SCHEMBL ID | 1647984 |
| MeSH ID | M0543826 |
Synonyms (34)
| Synonym |
|---|
| D09676 |
| 867257-26-9 |
| tecarfarin (usan/inn) |
| tecarfarin |
| benzoic acid, 4-((4-hydroxy-2-oxo-2h-1-benzopyran-3-yl)methyl)-, 2,2,2-trifluoro-1-methyl-1-(trifluoromethyl)ethyl ester |
| ati-5923 |
| 2,2,2-trifluoro-1-methyl-1-(trifluoromethyl)ethyl 4-((4-hydroxy-2-oxo-2h-1-benzopyran-3-yl)methyl)benzoate |
| wn1479yt50 , |
| unii-wn1479yt50 |
| tecarfarin [usan:inn] |
| ati 5923 |
| ati5923 |
| CHEMBL2105664 |
| 1,1,1,3,3,3-hexafluoro-2-methylpropan-2-yl 4-[(4-hydroxy-2-oxo-2h-chromen-3-yl)methyl]benzoate |
| tecarfarin [inn] |
| tecarfarin [usan] |
| 2,2,2-trifluoro-1-methyl-1-(trifluoromethyl)ethyl 4-((4-hydroxy-2-oxo-2h-chromen-3-yl)methyl)benzoate |
| tecarfarin [who-dd] |
| SCHEMBL1647984 |
| DTXSID90235788 |
| AKOS030535872 |
| DB12823 |
| HY-14854 |
| CS-0003597 |
| (1,1,1,3,3,3-hexafluoro-2-methylpropan-2-yl) 4-[(4-hydroxy-2-oxochromen-3-yl)methyl]benzoate |
| SB18978 |
| ati-5923; ati 5923; ati5923 |
| BCP31892 |
| Q27292724 |
| MS-28430 |
| 1,1,1,3,3,3-hexafluoro-2-methylpropan-2-yl 4-((4-hydroxy-2-oxo-2h-chromen-3-yl)methyl)benzoate |
| qflntqdovclqkw-uhfffaoysa-n |
| 1,1,1,3,3,3-hexafluoro-2-methylpropan-2-yl4-((4-hydroxy-2-oxo-2h-chromen-3-yl)methyl)benzoate |
| benzoic acid, 4-[(4-hydroxy-2-oxo-2h-1-benzopyran-3-yl)methyl]-, 2,2,2-trifluoro-1-methyl-1-(trifluoromethyl)ethyl?ester |
Research Excerpts
Toxicity
| Excerpt | Reference | Relevance |
|---|---|---|
| " Tecarfarin was well tolerated without serious adverse events." | ( Safety and Tolerability of Tecarfarin (ATI-5923) in Healthy Chinese Volunteers: Multiple Oral Dose-Escalation Phase I Trial. Chen, Z; Dai, X; Hu, W; Li, X; Wang, H; Wang, Z; Yu, X; Zhang, Y; Zhou, Q; Zhou, R, 2023) | 0.91 |
Pharmacokinetics
| Excerpt | Reference | Relevance |
|---|---|---|
| " To evaluate the pharmacokinetic (PK), pharmacodynamic (PD), and safety of tecarfarin, we performed single ascending dose (SAD) (n=66), multiple ascending dose (MAD) (n=43), and tecarfarin versus warfarin (n=28) studies in human volunteers." | ( Pharmacokinetics and pharmacodynamics of tecarfarin, a novel vitamin K antagonist oral anticoagulant. Albrecht, D; Canafax, DM; Combs, D; Druzgala, P; Ellis, D; Midei, MG; Milner, PG, 2017) | 0.46 |
Dosage Studied
| Excerpt | Relevance | Reference |
|---|---|---|
| " They have a slow onset and offset of action, narrow therapeutic window, marked dose-response variability, and multiple food and drug interactions, and require frequent coagulation monitoring and dose adjustments." | ( Emerging anticoagulant therapies for atrial fibrillation: new options, new challenges. Mangiafico, M; Mangiafico, RA, 2012) | 0.38 |
| " Dosing of study drugs was managed by a centralised dose control centre, which had access to genotyping." | ( A randomised, double blind comparison of tecarfarin, a novel vitamin K antagonist, with warfarin. The EmbraceAC Trial. Albrecht, D; Canafax, DM; Ellis, D; Fordyce, CB; Garcia, D; Midei, MG; Milner, PG; Weitz, JI; Whitlock, RP, 2016) | 0.43 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Research
Studies (10)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (10.00) | 29.6817 |
| 2010's | 8 (80.00) | 24.3611 |
| 2020's | 1 (10.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
Market Indicators
Research Demand Index: 17.44
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (17.44) All Compounds (24.57) |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 5 (50.00%) | 5.53% |
| Reviews | 1 (10.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 4 (40.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||